Eased Tensions On Korean Peninsula To Fuel Botanical Drug R&D?
Executive Summary
Herbal-derived drug development on the Korean peninsula is poised to get an initial boost once the relationship between the North and South improves, although it is uncertain how the possible easing of tensions between the two countries will broadly affect South Korea's pharma sector.
You may also be interested in...
Kaesong Complex A Starting Point For Two Koreas' Healthcare Cooperation?
As political talks gain momentum, the Kaesong Industrial Complex in North Korea could be the starting point of possible healthcare cooperation with the South, once the relationship between the two countries improves, a South Korean official report suggests.
Dong-A Ties With NeuroBo For Diabetic Neuropathy, Alzheimer's
Dong-A makes notable progress in botanical drug programs, reaching deals for its diabetic neuropathic pain and Alzheimer's disease drug assets with Boston-based NeuroBo Pharmaceuticals.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.